Presentation is loading. Please wait.

Presentation is loading. Please wait.

ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.

Published byJason Douglas Modified over 9 years ago

Similar presentations

Presentation on theme: "ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml."— Presentation transcript:

1 ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml Treatment-naïve or experienced Compensated cirrhosis allowed HIV infection on ART with HIV RNA 100/mm 3 Naggie S. NEJM 2015, July 21, ahead of print N = 335 SVR 12 –Co-formulated ledipasvir-sofosbuvir (LDV 90mg/SOF 400 mg) : 1 pill QD –ARV regimens : FTC and TDF + EFV or RAL or RPV  Objective –Primary endpoint : SVR 12 (HCV RNA < 25 IU/ml), with 2-sided 95% CI

2 N = 335 Mean age, years52 Female18% Race : white / black61% / 34% Body mass index, mean27 Genotype 1a / 1b / 475% / 23% / 2% Cirrhosis20% IL28B CC genotype24% HCV RNA log 10 IU/ml, mean6.7 HCV treatment experienced55% CD4 /mm3, median628 ARV regimen : EFV / RAL / RPV48% / 44% / 9% Discontinuation, N Protocol violation Lack of efficacy Death 96219621 Baseline characteristics and patient disposition ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print

3 SVR 12 (HCV RNA < 25 IU/ml), % (95% CI) 25 50 100 75 96.1* (93.5-97.9) % 94 (85.4-98.3) N 335 95.3 (90.6-98.1 Overall* 96 (92.8-98.1) 96.1 (89-99.2) 96.6 (93.7-98.5) 2507726867158 96.8 (93.1-98.8) 185 Naïve ExpriencedNo cirrhosisCirrhosis 1a Genotype 1b4 8 100 (63.1-100) * 2 on-treatment failures (noncompliance) ; 1 lost to follow-up ; 10 relapses ; 1 death (IVDU-related endocarditis/sepsis) ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print

4 SVR 12 (HCV RNA < 25 IU/ml), % (95% CI)  Significantly lower response in black patients (p < 0.001)  Response similar in patients who had undergone previous treatment and those who had not, in patients receiving various concomitant HIV antiretroviral regimens 25 50 100 75 96.4 (93.4-98.2) % 95.7 (92.7-97.7) N276 89.6 (82.5-94.5) Male 98.8 (93.3-100) 97.8 (94.6-99.4) 100 (90.3-100) 811853667115 99.5 (97.5-100) 217 BlackNon-black< 800,000≥ 800,000CC IL28B CTTT 69 88.4 (78.4-94.9) 94.9 (85.9-98.9) 59 Baseline HCV RNA (IU/ml) RaceSex Female ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print

5 Multivariate analysis of factors associated with virologic relapse Odds ratio (95% CI)2-sided p value Black race17.73 (2.66-infinity)0.0012 IL28B TT4.27 (0.89-27.5)0.0751 ARV : EFV3.26 (0.59-33.63)0.241  2 virologic breakthrough + 10 relapses  10 relapses –All black –7 had IL28B TT –8 were on EFV Virologic failure ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print

6  Patients with genotype 1 : deep sequencing of NS5A at baseline : 59/325 (18%) patients with NS5A variants (RAVs) –55/59 (93%) achieved SVR 12 –258/266 (97%) with no baseline NS5A RAVs achieved SVR 12  2 patients with virologic breakthrough : no baseline NS5A RAVs but emergence of NS5A RAVs at failure  10 relapses: NS5A RAVs at baseline in 4, and in 8 at the time of relapse  No NS5B S282T in any patient at baseline or virologic failure Virologic resistance testing ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print

7  Stable CD4 through treatment and follow-up; No patient had confirmed HIV rebound Adverse events, N (%) ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print N = 335 Adverse events257 (77) Grade 3 ‒ 4 adverse event 14 (4) Serious adverse event8 (2) Treatment discontinuation due to adverse event0 Death 1 (<1) Staph. aureus sepsis in IV drug user Headache83 (25) Fatigue71 (21) Diarrhea36 (11) Nausea33 (10) Arthralgia22 (7) Upper respiratory tract infection 18 (5) Grade 3 ‒ 4 laboratory abnormality 36 (11)

8  Summary –In this Phase III study of 335 HIV/HCV-coinfected patients, 96% achieved SVR 12 after 12 weeks of a once-daily, single-tablet regimen of LDV/SOF Prior HCV treatment status or the presence or absence of cirrhosis did not impact outcome In contrast to larger studies among monoinfected patients, a lower response rate was observed among coinfected black patients treated with LDV/SOF (SVR 12 : 90%) –LDV/SOF was well tolerated, with no treatment discontinuations due to adverse events and no adverse impact on HIV disease or its treatment ION-4 ION-4 Study: LDV/SOF in HIV co-infection Naggie S. NEJM 2015, July 21, ahead of print

Download ppt "ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml."

Similar presentations

CROI 2015, Seattle Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: ION-4 Susanna Naggie 1, Curtis Cooper 2, Michael Saag.

CROI 2015, Seattle Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: ION-4 Susanna Naggie 1, Curtis Cooper 2, Michael Saag.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.

LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.
OBV/PTV/r Open label 18-70 years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = 107 18-70 years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.

SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.

Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.

FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.
ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
No HBV or HIV co-infection

No HBV or HIV co-infection
C-EDGE co-infection study: grazoprevir/ elbasvir in HIV coinfection GZR/EBR 100/50 mg qd N = 218  Design W12 W24 C-EDGE co-infection Rockstroh JK. Lancet.

C-EDGE co-infection study: grazoprevir/ elbasvir in HIV coinfection GZR/EBR 100/50 mg qd N = 218  Design W12 W24 C-EDGE co-infection Rockstroh JK. Lancet.
SMV 150 + SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : 1 18-70 years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥ 10.000.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind 18-70 years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.
NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.

NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.

Similar presentations

Ads by Google